AI Engines For more Details: Perplexity Kagi Labs You
Multiple Sclerosis (MS): Ibudilast has shown promise in the treatment of multiple sclerosis, a chronic autoimmune disorder affecting the central nervous system. It may help reduce inflammation and slow down the progression of the disease.
Asthma: Ibudilast has bronchodilator properties, meaning it helps to widen the airways in the lungs. This can be beneficial in the treatment of asthma, a condition characterized by airway inflammation and constriction.
Chronic Obstructive Pulmonary Disease (COPD): Similar to its effects in asthma, ibudilast's bronchodilator properties may help alleviate symptoms in COPD, a group of progressive lung diseases including chronic bronchitis and emphysema.
Neuroinflammation: Ibudilast has been investigated for its potential to reduce neuroinflammation, which is implicated in various neurological disorders such as Alzheimer's disease, Parkinson's disease, and neuropathic pain.
Depression and Anxiety: Some research suggests that ibudilast may have antidepressant and anxiolytic (anti-anxiety) effects, possibly due to its anti-inflammatory actions in the brain.
Substance Use Disorders: Ibudilast has been studied for its potential to reduce cravings and withdrawal symptoms associated with substance use disorders, particularly in alcohol and opioid dependence.
Chronic Pain: Ibudilast's anti-inflammatory and neuroprotective properties may offer relief from chronic pain conditions such as neuropathic pain and fibromyalgia.
Stroke Recovery: There is some evidence to suggest that ibudilast may aid in stroke recovery by reducing inflammation and promoting neural repair and regeneration.
Glaucoma: In ophthalmology, ibudilast has been explored for its potential to lower intraocular pressure and protect retinal ganglion cells, making it a possible treatment option for glaucoma.
Retinal Disorders: Ibudilast's neuroprotective effects extend to the retina, where it may help preserve retinal function and prevent vision loss in conditions such as diabetic retinopathy and retinal degenerative diseases.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 1.2 | 0.3 | 3 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.2 | 0 |
Allergic Rhinitis (Hay Fever) | 1.4 | 1.4 | |
Allergies | 1 | 0.1 | 9 |
Allergy to milk products | 0.9 | 0.5 | 0.8 |
Alopecia (Hair Loss) | 0.3 | 0.3 | |
Alzheimer's disease | 0.9 | 1.6 | -0.78 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 0.6 | 1 |
Ankylosing spondylitis | 1.2 | 0.8 | 0.5 |
Anorexia Nervosa | 0.2 | 0.6 | -2 |
Antiphospholipid syndrome (APS) | 1.3 | 1.3 | |
Asthma | 0.1 | 0.4 | -3 |
Atherosclerosis | 0.9 | -0.9 | |
Atrial fibrillation | 0.9 | 0.7 | 0.29 |
Autism | 2.7 | 2.4 | 0.13 |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 0.7 | 0.5 | 0.4 |
Brain Trauma | 0.4 | -0.4 | |
Carcinoma | 0.8 | 0.5 | 0.6 |
Celiac Disease | 1.2 | 0.5 | 1.4 |
Cerebral Palsy | 0.1 | 0.4 | -3 |
Chronic Fatigue Syndrome | 1.8 | 2.7 | -0.5 |
Chronic Kidney Disease | 1.3 | 0.7 | 0.86 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.5 | -4 |
Chronic Urticaria (Hives) | 1 | 0.5 | 1 |
Coagulation / Micro clot triggering bacteria | 1.1 | 0.2 | 4.5 |
Colorectal Cancer | 2 | 0.1 | 19 |
Constipation | 0.8 | 0.2 | 3 |
Coronary artery disease | 0.7 | 0.3 | 1.33 |
COVID-19 | 3.1 | 2.9 | 0.07 |
Crohn's Disease | 3.5 | 1.7 | 1.06 |
cystic fibrosis | 0.8 | 0.4 | 1 |
deep vein thrombosis | 0.8 | 0.2 | 3 |
Depression | 3 | 3.1 | -0.03 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.9 | 0.6 | 0.5 |
Endometriosis | 1.6 | 0.1 | 15 |
Epilepsy | 0.9 | 1 | -0.11 |
Fibromyalgia | 1.2 | 1.5 | -0.25 |
Functional constipation / chronic idiopathic constipation | 2.7 | 1.3 | 1.08 |
gallstone disease (gsd) | 0.6 | 0.2 | 2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0 | 0 |
Generalized anxiety disorder | 1.4 | 0.6 | 1.33 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0 | 0 | |
Gout | 0.3 | -0.3 | |
Graves' disease | 0.4 | 0.2 | 1 |
Halitosis | 0.2 | 0 | 0 |
Hashimoto's thyroiditis | 0.4 | 0.2 | 1 |
Hidradenitis Suppurativa | 0 | 0 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.4 | 2 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
hyperglycemia | 0.3 | 0.4 | -0.33 |
hypertension (High Blood Pressure | 0.7 | 1.3 | -0.86 |
Hypothyroidism | 0.3 | -0.3 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1.7 | -1.7 | |
Inflammatory Bowel Disease | 2.1 | 2.2 | -0.05 |
Insomnia | 0.2 | 0.4 | -1 |
Intelligence | 1 | 0 | 0 |
Intracranial aneurysms | 0.4 | 0.4 | |
Irritable Bowel Syndrome | 1.7 | 1.5 | 0.13 |
Liver Cirrhosis | 1.4 | 0.8 | 0.75 |
Long COVID | 2.9 | 1.5 | 0.93 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.3 | 0.3 | |
ME/CFS with IBS | 0.1 | 0.8 | -7 |
ME/CFS without IBS | 0.9 | 0.5 | 0.8 |
Menopause | 0.1 | 0.1 | |
Metabolic Syndrome | 3 | 2.5 | 0.2 |
Mood Disorders | 3.6 | 3.1 | 0.16 |
multiple chemical sensitivity [MCS] | 0 | 0 | |
Multiple Sclerosis | 0.3 | 2 | -5.67 |
Multiple system atrophy (MSA) | 0 | 0 | |
Neuropathy (all types) | 0 | 0.3 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.8 | -1 |
Obesity | 2.1 | 1.1 | 0.91 |
obsessive-compulsive disorder | 2.7 | 1.3 | 1.08 |
Osteoarthritis | 1.2 | 1.2 | |
Osteoporosis | 0.6 | 0.2 | 2 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 1.1 | 1.7 | -0.55 |
Polycystic ovary syndrome | 1.2 | 0.4 | 2 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.3 | -2 |
Premenstrual dysphoric disorder | 0.2 | -0.2 | |
primary biliary cholangitis | 0.5 | -0.5 | |
Psoriasis | 1.2 | 1.2 | 0 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 1.4 | 0.29 |
Rosacea | 0.3 | -0.3 | |
Schizophrenia | 1.7 | 0.6 | 1.83 |
scoliosis | 0.3 | 0.3 | |
Sjögren syndrome | 0.6 | 1 | -0.67 |
Sleep Apnea | 0.3 | 0.7 | -1.33 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
Stress / posttraumatic stress disorder | 1.3 | 0.7 | 0.86 |
Systemic Lupus Erythematosus | 2.2 | 0.3 | 6.33 |
Tic Disorder | 0.5 | 0 | 0 |
Tourette syndrome | 0.2 | -0.2 | |
Type 1 Diabetes | 1.7 | 0.7 | 1.43 |
Type 2 Diabetes | 3.3 | 3.3 | 0 |
Ulcerative colitis | 1.3 | 2.1 | -0.62 |
Unhealthy Ageing | 1.9 | 0.8 | 1.37 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.